{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+III&page=21", "query": { "condition": "Phase III", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 10486, "total_pages": 1049, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+III&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+III&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T13:46:26.828Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04371666", "title": "Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "Pamrevlumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyntra Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "MALE", "summary": "12 Years and older · Male only" }, "enrollment_count": 98, "start_date": "2020-08-10", "completion_date": "2023-08-17", "has_results": true, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-10-30T13:46:26.828Z", "location_count": 24, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 21 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04371666" }, { "nct_id": "NCT03996369", "title": "Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Etrasimod", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arena Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 354, "start_date": "2020-09-15", "completion_date": "2021-12-07", "has_results": true, "last_update_posted_date": "2022-12-21", "last_synced_at": "2026-10-30T13:46:26.828Z", "location_count": 62, "location_summary": "Dothan, Alabama • Mobile, Alabama • Sun City, Arizona + 54 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03996369" }, { "nct_id": "NCT03442751", "title": "Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Progressive Keratoconus" ], "interventions": [ { "name": "Test Article A", "type": "DRUG" }, { "name": "Test Article B", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "KXL medical device system", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Glaukos Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "12 Years to 55 Years" }, "enrollment_count": 201, "start_date": "2018-04-06", "completion_date": "2020-08-10", "has_results": true, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-10-30T13:46:26.828Z", "location_count": 1, "location_summary": "Waltham, Massachusetts", "locations": [ { "city": "Waltham", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03442751" }, { "nct_id": "NCT04068103", "title": "Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Colon Adenocarcinoma", "Stage IIA Colon Cancer AJCC v8" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Patient Observation", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 635, "start_date": "2019-12-16", "completion_date": "2026-06-21", "has_results": true, "last_update_posted_date": "2025-05-07", "last_synced_at": "2026-10-30T13:46:26.828Z", "location_count": 932, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 639 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04068103" }, { "nct_id": "NCT03443973", "title": "Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "Gantenerumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 975, "start_date": "2018-08-22", "completion_date": "2022-11-28", "has_results": true, "last_update_posted_date": "2024-01-17", "last_synced_at": "2026-10-30T13:46:26.828Z", "location_count": 47, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 39 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03443973" }, { "nct_id": "NCT06439602", "title": "Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gout", "Arthritis, Gouty", "Hyperuricemia", "Gout Chronic" ], "interventions": [ { "name": "AR882 50 mg", "type": "DRUG" }, { "name": "AR882 75 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arthrosi Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 818, "start_date": "2024-06-26", "completion_date": "2026-04-10", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-30T13:46:26.828Z", "location_count": 52, "location_summary": "Foley, Alabama • Anchorage, Alaska • Peoria, Arizona + 47 more", "locations": [ { "city": "Foley", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06439602" }, { "nct_id": "NCT05899673", "title": "An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alpha1-Antitrypsin Deficiency" ], "interventions": [ { "name": "Fazirsiran Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2023-08-08", "completion_date": "2033-05-02", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-10-30T13:46:26.828Z", "location_count": 5, "location_summary": "La Jolla, California • Redwood City, California • Gainesville, Florida + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Redwood City", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05899673" }, { "nct_id": "NCT03630354", "title": "EXERCISING TOGETHER for Couples Coping With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Breast Carcinoma", "Colorectal Carcinoma", "Malignant Solid Neoplasm", "Prostate Carcinoma", "Stage I Colorectal Cancer AJCC v8", "Stage I Prostate Cancer AJCC v8", "Stage II Colorectal Cancer AJCC v8", "Stage II Prostate Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Exercise Intervention (supervised)", "type": "BEHAVIORAL" }, { "name": "Exercise Intervention (unsupervised)", "type": "BEHAVIORAL" }, { "name": "Informational Intervention", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "35 Years to 80 Years" }, "enrollment_count": 496, "start_date": "2019-01-18", "completion_date": "2024-03-31", "has_results": true, "last_update_posted_date": "2025-07-01", "last_synced_at": "2026-10-30T13:46:26.828Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03630354" }, { "nct_id": "NCT00069095", "title": "A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Oxaliplatin 130 mg/m^2", "type": "DRUG" }, { "name": "Capecitabine 1000 mg/m^2", "type": "DRUG" }, { "name": "Bevacizumab 7.5 mg/kg", "type": "DRUG" }, { "name": "Placebo for bevacizumab 7.5 mg/kg", "type": "DRUG" }, { "name": "Oxaliplatin 85 mg/m^2", "type": "DRUG" }, { "name": "Leucovorin 200 mg/m^2", "type": "DRUG" }, { "name": "Fluorouracil 400 mg/m^2", "type": "DRUG" }, { "name": "Bevacizumab 5 mg/kg", "type": "DRUG" }, { "name": "Placebo for bevacizumab 5 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2035, "start_date": "2003-07", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2016-10-06", "last_synced_at": "2026-10-30T13:46:26.828Z", "location_count": 49, "location_summary": "Berkeley, California • Fountain Valley, California • Fullerton, California + 44 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Gilroy", "state": "California" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00069095" }, { "nct_id": "NCT00376961", "title": "S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 68, "start_date": "2006-08", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2017-11-06", "last_synced_at": "2026-10-30T13:46:26.828Z", "location_count": 147, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 95 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00376961" } ] }